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Abstract
Many symptoms of multiple sclerosis may affect the ear, nose and throat. The most common otolaryngologic symptoms 
of multiple sclerosis are speech disorders, followed by sleep disorders, vertigo and disequilibrium, dysphagia, smell 
alterations, and hearing loss. Less common symptoms include sialorrhea, facial palsy, taste alterations, trigeminal 
neuralgia and tinnitus. The origin of otolaryngologic symptoms in multiple sclerosis is mainly central, although increasing 
evidence also suggests a peripheral involvement.
Otolaryngologic symptoms in multiple sclerosis may have different clinical presentations; they can appear in different 
stages of the pathology, in some cases they can be the presenting symptoms and their worsening may be correlated 
with reactivation of the disease. Many of these symptoms significantly affect the quality of life or patients and lead to 
increased morbidity and mortality.
Otolaryngologic symptoms are common in multiple sclerosis; however, they are often overlooked. In many cases, they 
follow the relapsing-remitting phases of the disease, and may spontaneously disappear, leading to a delay in multiple 
sclerosis diagnosis. Clinicians should be aware of otolaryngologic symptoms of multiple sclerosis, especially when 
they are associated to neurologic symptoms, as they may be early signs of a still undiagnosed multiple sclerosis or 
could help monitor disease progression in already diagnosed patients.
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INTRODUCTION
Multiple Sclerosis (MS) is an autoimmune-mediated 
neurodegenerative demyelinating disease characterized 
by relapsing and remitting phases with invalidating long-
term sequelae especially in late-diagnosed cases1. MS 
is one of the most common neurodegenerative diseases 
with a prevalence that vary with geography and ethnicity 
ranging from 2 per 100.000 in Japan to more than 100 per 
100.000 in Northern Europe and North America2. MS has 
a strong gender effect, with prevalence in women almost 
double compared to men2.
The etiology and pathogenesis of MS remains unclear3-5; 
it may be correlated to genetic predisposition6, to 
environmental factors and food habits7, and to the 
action of viruses that induce the expression of recessive 
genotypes8. Any of these may induce an altered 
autoimmune response of the central nervous system that 
leads to destruction of myelin associated with activated 
microglia9,10. Microglia, a cell population that belongs to 
the macrophage family, can change its phenotype by 
passing from an aggressive-demyelinating form (M1) to 
a protective-demyelinating form (M2)9,10. The alternation 
between these two forms is modulated by several 
factors10 and may explain the temporariness of many MS 
symptoms and their natural regression. However, besides 
the presence of microglia at sites of demyelination, its 
role in the pathogenesis of MS is only beginning to be 
revealed9.
MS clinical presentation and progression are characterized 
by high variability and diversity11. Common symptoms 
include weakness or numbness in one or more limbs, 
optic neuritis, tremor and ataxic gait from cerebellar 
dysfunction, double vision, dysarthria, or dizziness and 
fatigue12. Most symptoms have an acute onset; however, 
the pattern of presentation can be highly variable, and 
symptoms may fluctuate considerably or even progress 
in correlation with the relapsing/remitting phases of the 
disease10,12.
Many symptoms of MS may affect the ear, nose and 
throat. They include hearing loss, tinnitus, vertigo and 
disequilibrium, facial palsy, dysphonia, dysphagia, 
sialorrhea, trigeminal neuralgia and neuropathy, sleep 
disorder and taste and smell alterations. The prevalence 
of otolaryngologic symptoms in patients with MS may 
significantly vary; they present in different stages of the 
pathology (early- or late-MS) and their worsening may 
be correlated with the reactivation of MS1,10. Prevalence 
of the otolaryngologic symptoms that may present in 
patients with MS is detailed in Table 1.
The origin of otolaryngologic symptoms in MS is mainly 
central, although increasing evidence also suggests a 
peripheral involvement5,9,13,14. O’Malley et al. studied the 
temporal bones of patients with systemic auto-immune 
diseases and Sensorineural Hearing Loss (SNHL) or 
vertigo and identified microglia in the inner ear15; however, 
the specific phenotype was not identified. Other authors 
have shown that microglia can migrate from the brain to 
the close neural structures14,16 following inflammation. It 
can be therefore speculated that microglia could migrate 
through the internal auditory canal reaching the cochlea 
and determining the demyelination of inner ear structures 
such as hair cells and spiral ganglion14. The possible 
migration of microglia to the periphery may determine 
not only audio-vestibular symptoms, but also other 
otolaryngologic symptoms (Figure 1).
Otolaryngologic symptoms, as many others in MS, tend 
to be transient and regress spontaneously. Most of them, 
especially when the exact pathogenesis is unclear, are 
treated during the acute phase with corticosteroids. 
Steroids, thanks to their combined immune-suppressant/
anti-inflammatory activity, can rapidly resolve the 
symptoms, but may also lead to a delay in the diagnosis 
of MS. 
The high variability of presentation and different 
characteristics of otolaryngologic symptoms often lead to 
a delay in the definite diagnosis of MS. The aim of this 
review is to describe and discuss current evidences and 
highlight recent findings of the otolaryngologic symptoms 
of MS.
OTOLARYNGOLOGIC SYMPTOMS IN MULTIPLE 
SCLEROSIS
Hearing loss and tinnitus
Several studies have documented the relationship 
between MS and hearing loss and tinnitus16-20. Hearing 
deficits in MS present in the form of sudden, progressive 
or fluctuating SNHL they may appear in the early stages of 
the disease, often as presenting symptoms, or during the 
late stages indicating a disease progression as a result of 
a progressive involvement of the hearing pathways17,19,20.
Sudden SNHL is more common in the early stages (within 
two years from diagnosis), while progressive SNHL 
in late stages (after five years)16-20. Often, hearing loss 
can fluctuate; this may be related to relapsing/remitting 
Otolaryngologic symptom Prevalence in multiple sclerosis
Dysphonia 44%-70%
Dysarthria 40%-62%
Sleep Disorders 25%-54%
Vertigo 20%-35%
Dysphagia 24%-37%
Smell alterations 15%-23%
Hearing loss 0.7%-25%
Sialorrhea 5%-10%
Facial palsy 7%
Taste alterations < 5%
Trigeminal neuralgia-sensory neuropathy  0.3%-2%
Tinnitus 1%
Table 1. Prevalence of the otolaryngologic symptoms that may 
present in patients with MS.
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or derive from central nervous system demyelination, 
especially in cases in which no auditory alterations are 
evident 18,40.
Audiological investigations as tonal and speech 
audiometry, Auditory Brainstem Responses (ABR), and 
transient (TEOAE) or Distortion Product Otoacoustic 
Emissions (DPOAE) are crucial to correctly describe 
and characterize hearing deficits in patients with MS. 
Often, clinical audiometry is not able to detect deficits 
in MS patients possibly due to forms of hidden hearing 
loss30,31,40, and ABR is necessary16. A recent review of 
the literature that included 47 studies and 1533 patients 
evaluated, among other tests, the role of ABR in MS 
patients, showing that it was abnormal in the majority of 
MS patients during the active phase and remained altered 
in nearly ¼ of the patients even after complete hearing 
recovery occurred16. ABR has an elevate sensitivity 
and specificity for the detection of demyelination in 
the auditory pathways of patients with MS. In fact, the 
increased latencies in the conduction of the auditory 
impulse and the absence of wave V can be signs of central 
alteration41. Speech audiometry is particularly important 
to highlight the difficulty in speech perception-especially 
in noise42 that is common in MS patients following 
abnormal auditory processing43 or cognitive deficit that 
altered the word recognition ability44. In addition, attention 
and auditory discrimination, which are crucial aspects in 
binaural perception and in the integration of sounds, can 
be compromised in MS patient43. TEOAE and DPOAE 
phases that occur during the course of MS or to the use 
of corticosteroids which are able to fight the systemic 
inflammation generated by MS. In many cases, even in the 
presence of lesions in the auditory pathways at Magnetic 
Resonance Imaging (MRI), there are no clinically evident 
hearing deficits19.
The origin of SNHL in MS can be central or peripheral, 
following demyelination of central or peripheral audio-
vestibular pathways that acts as an "on-off" mechanism; 
some authors have observed patients with hearing deficit 
and altered electrophysiologic responses indicative of 
demyelination without evidence of lesions at MRI17.
Hearing loss may be a presenting symptom of MS21; 
however, although its importance as an early symptom of 
MS has been described by many studies, its significance is 
largely underestimated. This may be due to its temporary 
nature and the good response to corticosteroid treatment; 
in fact, nearly 90% of patients with sudden SNHL are 
given an initial diagnosis of “idiopathic” sudden SNHL22.
Tinnitus, the perception of a sound when no external 
stimulation is present23, is commonly found in patients 
with hearing loss following presbycusis24,25, noise 
exposure26,27 or other auditory conditions28,29; however, 
it can also be found in patients with a clinically normal 
hearing, following synaptopathy30,31, somatic disorders32-37 
and psychological dysfunctions38.
Tinnitus has been described in many autoimmune 
conditions39; in patients with MS it may follow SNHL 
Figure 1. The image shows the auditory, facial and vestibular pathways. Lesions in pons, medulla and brainstem located in one or more area of these 
pathways may generate a symptom. Multiple symptoms can be observed especially in the late stages of multiple sclerosis, due to the dissemination 
of demyelinating lesions.
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may identify damages in specific areas of the cochlea 
sustained by a peripheral microglia aggression; however, 
so far their use has been always associated with ABR in 
clinical studies45 because the evidence on the cochlea 
involvement in MS is still unclear.
SNHL should be always considered in the differential 
diagnosis of MS, especially in young subjects without a 
history of hearing impairment16. Otolaryngologists should 
always consider the possibility that SNHL, especially in its 
sudden form, may be an early symptom of MS.
Vertigo and Disequilibrium
Vertigo and disequilibrium are common symptoms in 
MS46,47. The origin of vertigo can be peripheral, following 
the involvement of the cochlea48, or–mainly-central, 
due to demyelinating lesions affecting the vestibular 
pathways such as the vestibular nuclei46. In some 
cases, it may follow the involvement of both the cochlea 
and the vestibular pathways. The origin of vertigo and 
disequilibrium in MS patients is more often attributed to 
stiffness, musculoskeletal weakness and ocular diseases 
rather than to the involvement of the vestibular pathways 
and of the inner ear47,49.
The electrophysiologic investigation with Vestibular 
Evoked Myogenic Potential (VEMP) has been recently 
proposed to identify areas of demyelination in the 
vestibular pathways of MS patients50. Furthermore, 
cervical-VEMPs can exclude the ocular involvement 
that may modify the sensitivity of VEMPs by interfering 
with the vestibular responses through ocular fixation 
compensation by allowing identification of the specific 
areas affected from demyelination51.
The study of nystagmus with Frenzel goggles allows the 
identification of nystagmus characteristics as direction, 
latency, adaptation and fatigue. Patients with MS typically 
present a multidirectional nystagmus without latency52; 
this may contribute to differential diagnosis by excluding 
other condition such as vestibular neuritis, Ménière 
Disease and benign positional paroxysmal vertigo48,53,54. 
Electronystagmography can be used in differential 
diagnosis to correctly identify which area (brain, pons, 
medulla o cerebellum) is affected from the demyelination.
Facial Palsy
Facial palsy may be found in MS patients55, sometimes 
as a presenting symptom56,57. Facial palsy may follow a 
lesion in the central facial pathways, including the motor 
cortex or the facial nuclei58 or be due to a peripheral 
involvement of the facial nerve following a progressive 
demyelization of the peripheral axon55.
In both cases, a facial palsy with the typical characteristic 
of a peripheral facial paralysis may be the onset symptom 
of MS30-32. Usually, facial palsy may involve all muscle of 
the hemiface similar to a Bell’s palsy58,59 by meaning that 
the demyelinating lesions are distributed in both brain 
hemisphere and in particular in the area of motor cortex 
with involvement of posterior limb of internal capsule and 
the corticobulbar tract (Figure 2)58.
In case of peripheral involvement of the facial pathways, 
the lesion is commonly located in the Roof Entry Zone60, 
consistently with the theory of microglia migration9.
Differential diagnosis with MS in cases of facial palsy is of 
paramount importance to avoid a delay in MS diagnosis. 
Due to the rarity of the peripheral involvement (facial nerve 
outside the stylomastoid foramen), an Electromyography 
may be not useful for a correct diagnosing a MS-related 
facial palsy. MS should be considered when there’s no 
improvement after corticosteroid therapy or in case 
Figure 2. The image shows the facial pathways. Facial palsy will assume the typical aspect of a peripheral form due to the spread of demyelinating 
lesion in both brain hemispheres; if the lesion is instead in a single hemisphere the palsy will have the typical aspect of a central form.
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of short term recurrence; in these cases second-level 
investigations such as MRI to identify the demyelinating 
lesions should be performed61,62.
Trigeminal Neuralgia and Trigeminal Sensory 
Neuropathy 
Maxillofacial manifestations such as trigeminal neuralgia 
and trigeminal sensory neuropathy have been reported 
in MS63.
Trigeminal neuralgia has been reported in MS with 
prevalence near 2% of cases64; it usually appears after the 
diagnosis of MS has been made although it can be the first 
manifestation of the disease in 0.3% of cases65. Trigeminal 
neuralgia in MS is characterized by paroxysmal severe 
pain that only lasts for a few seconds; however, it can 
return multiple times during the day66. Curiously, Hartman 
et al. observed that in MS the trigeminal neuralgia may be 
triggered by an auditory stimulus67.
Sensory neuropathy in MS is often bilateral, progressive 
and irreversible, with a sudden and often painful onset. 
It mainly affects the second and third divisions of the 
trigeminal nerve68. Neuropathy of the mental nerve causes 
numbness of the lower lip and chin, with or without pain69.
The origin of trigeminal symptoms in MS is commonly 
a central lesion in the trigeminal nuclei or in the more 
superior trigeminal pathway70; Nakashima et al. showed 
that women affected from MS and trigeminal disorders 
presented demyelinating lesions in the linear pontine 
trigeminal root71.
The trigeminal nerve function can be investigated using 
electrophysiologic tests72; the most common finding in 
MS is the presence of electrophysiologic impairment with 
increased amplitudes and delayed latencies.
Trigeminal neuralgia in MS may be treated 
pharmacologically; botulin toxin injection may be helpful 
to alleviate pain. Surgery should be avoided because it 
does not offer long term relief (<2 years) in patients with 
MS73.
Smell alterations
Smell alterations may be present in MS with a prevalence 
ranging from 15% to 45%74-79 and are mainly described 
during the active phases of the disease. Olfactory 
disorders in MS often begins with an altered perception of 
smell (dysosmia) that progressively worsen to complete 
anosmia80,81.
The causes of smell alterations in MS can be both 
peripheral and central demyelination; in the former case, 
they may be correlated to the damage of the olfactory 
receptors, while in the latter demyelination plaques that 
develop in the olfactory bulb or in the cortex–especially 
the inferior frontal and temporal-lobe regions-may be 
responsible of the symptoms. In particular, the smell 
threshold alteration is often associated with a peripheral 
damage, while odor discrimination is related to a central 
process75,77,78,82,83.
The diagnosis of olfactory alterations can be made using 
olfactometry84, and a worsening of this condition may be 
an indicator of disease progression due to the increasing 
of number of lesion or to the extension of demyelinating 
areas74,79.
Taste alterations
Taste alterations have been reported in nearly 20% of 
MS patients75,80, although much controversy still exist 
on the exact prevalence of this symptom due to its strict 
correlation with smell80,85. Taste alterations may appear as 
presenting symptoms or later in the progression of the 
disease, and often have a temporary nature associated to 
the inflammatory phases of MS. Current evidence suggest 
a central origin of these alterations85,86; in particular, 
transitory taste alterations may follow demyelination in 
the lateral part of midpontine tegmentum, while in case 
of a persistent symptom, the demyelinating lesions may 
occupy midbrain or the caudal portion. Clinical evaluation 
of taste alterations can be done using electrogustometry, 
chemogustometry and self-administered questionnaires87. 
Electrogustometry may be very useful for diagnosis and 
monitoring of MS; Sarmiento et al. showed that patients 
with MS presented increased threshold and difficulties to 
identify tastants for all four classic taste qualities on both 
anterior (VII) and posterior regions of the tongue (IX)88 
and that such difficulties increased with the progression 
of MS.
Sialorrhoea
Sialorrhoea and drooling are conditions of hypersalivation89 
that may be found in many neurodegenerative disorders90; 
in MS they are usually found in the advanced stages 
of the disease. Sialorrhea is an invalidating condition 
with serious implications on quality of life91. It can be a 
primary dysfunction of cholinergic signals, characterized 
by a hyper production of saliva from the major salivary 
glands, or it could follow an impairment of swallowing 
coordination90.
Both conditions may be related to a central lesion in 
the superior salivary nuclei for primary forms and in the 
swallowing pathways for secondary forms. In case of 
advanced MS stage, multiple lesions and the spread 
of demyelination plaques in the brain and medulla may 
explain the presence of sialorrhea
Sialorrhea may be treated with botulin toxin injected in the 
salivary glands to reduce the salivary production90,92-94, 
with drugs that inhibit saliva production95 or with physical 
rehabilitation to improve the swallowing coordination56.
Dysphagia
Abnormalities of swallowing are commonly encountered 
in MS, especially in the most disabled patients [96]; 
dysphagia is a symptom that can be found in 20 to 30% 
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of these patients [97, 98]. Dysphagia is characterized 
by the alteration in the progression of the bolus through 
oropharynx, hypopharynx and esophagus due to a loss 
of swallowing coordination [98]; muscle stiffness or 
weakness, difficulties in concentration and expiratory/
inspiratory discoordination may further aggravate the 
symptom [99]. Dysphagia can rarely be a presenting 
symptom of MS, while it is more often seen in the late 
stage of the disease. This may follow the increased 
number of lesions in the swallowing pathways that impact 
the esophageal phase (upper oesophageal sphincter 
dysfunction), the increased stiffness of the tongue (buccal 
phase), and the worsening of weakness of the mouth and 
neck muscles (pharyngeal-laringeal phase) that alter the 
swallowing progression96-99.
Videofluoroscopy studies showed that MS patients 
present swallowing abnormalities such as dysmotility and 
impaired retraction of the tongue, delay, prolongation or 
even loss of the pharyngeal phase, upper esophageal 
sphincter dysfunction, deficit of laryngeal closure, and 
diminished laryngeal or pharyngeal sensitivity100,101.
Dysphagia is an important cause of dehydration and 
malnutrition in MS patients leading to a high mortality 
rate100.
Swallowing alterations in MS patients can be evaluated 
through patient’s history, bedside screening examination, 
fiberoptic endoscopic evaluation of swallowing to 
evaluate the buccal and pharyngo-laryngeal phases and 
video-fluoroscopy101. Self-administered questionnaires, 
such as the DYMUS (Dysphagia in Multiple Sclerosis) 
questionnaire, have also been proposed to evaluate 
symptom progression97.
Electromyography should be performed before treatment 
to identify the affected muscles and better address 
treatment with botulin toxin alone102 or associated 
with physical rehabilitation103. Alfonsi et al. showed 
that 92% of patients in the later stage of MS presented 
prolonged electromyographic activity of suprahyoid/
submental muscle (buccal phase) and an increased 
time in the laryngo-pharyngeal phase104, suggesting to 
add electromyography to the diagnostic exams to define 
treatment.
Speech disorders 
Nearly 40% of subjects with a diagnosis of MS have 
speech disorders such as dysphonia and dysarthria and, 
at a lesser extent, comprehension disorders105,106.
Dysphonia in MS may follow alteration of the vocal fold 
control and in voice production107; symptoms include 
hoarseness and poor control of volume and pitch108. 
Transitory spasms of vocal fold may induce sudden 
and temporary interruptions of voice109. Dysarthria is 
predominantly a mixed form with ataxic and spastic 
speech characteristics110, typically scanning speech.
Dysphonia is more common in the early stage of MS and 
in some cases it may be a presenting symptom of MS109; 
it may appear as a transitory hypofunctional dysphonia 
that recovery spontaneously after 15-20 days107, or as 
an episode of spastic dysphonia without evidence of 
laryngeal pharyngeal reflux109,111. Dysarthria is more 
common during the late stage of MS.
Both dysphonia and dysarthria may be correlated to an 
alteration of the expiratory and phonatory times112. Nordio 
et al. showed that a reduction of the expiratory and 
phonatory time in patients with MS was directly correlated 
with the increase of the Expanded Disability Status Scale 
(EDSS) score112, reporting more speech difficulties during 
the relapsing phases of MS and suggesting that they may 
be correlated to the severity of the speech disorder109,112.
Speech disorders are mainly correlated to demyelinating 
lesions in the central speech pathways rather than to a 
peripheral involvement of recurrent nerve107; in particular, 
these disorders may be observed in case of lesions located 
in the subthalamic regions113 and in the periaqueductal 
area108. They mainly follow a progressive weakness of the 
musculature that can involve all the speech mechanisms 
and provoke a relevant decrease of verbal communication 
skills. The “fatigue” component is extremely relevant in 
the expiration mechanism and the stiffness that affects 
muscle involved in speech production and emission may 
further worsen speech112.
Speech disorders in patient with MS may be 
investigated with perceptual, acoustic, aerodynamic, 
and physiological assessments though computer 
or laboratory-based practices114. Specifically, voice 
characteristic can be evaluated with the Multi-Dimensional 
Voice Program (MDVP)115, electroglottography116 and 
videostroboscopy117. These methods can measure 
phonation instability108, alterations of voice parameters 
in specific frequency bands, jitter, and shimmer118 by 
offering a detailed investigation of voice features119.
Many studies have revealed that an early treatment of MS 
and a speech rehabilitation therapy in MS patients with 
speech disorders can significantly help in controlling the 
progressive alteration in the intelligibility of the speech 
capacity120-122.
Sleep disorders
Sleep Disorders (SD), including Obstructive Sleep Apnea 
(OSA) and Central Sleep Apnea (CSA), are significantly 
underestimated comorbidities in patients with MS123 with 
a significant worsening of quality of life124. SD may worsen 
fatigue, common in patients with MS125,126; however, 
the extent to which OSA and CSA contribute to these 
symptoms remains unclear127,128.
There may be significant bidirectional relationships 
between SD and MS. Previous studies have demonstrated 
that the prevalence and severity of SD are higher in persons 
with MS129,130. Furthermore, it has been demonstrated that 
among patients with MS, OSA and SD are significantly 
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associated with diminished visual memory, verbal 
memory, executive function, attention, processing speed, 
and working memory131.
The lesions involving the brainstem and the spinal 
cord could alter breathing control and upper airway 
muscle activity. The physiological respiration rate 
and synchronism during the night comprehends an 
increase of the pharyngeal tone; the tone is strongly 
hold due to the coordination between the palatal and 
genioglossus muscles and the action of the X and XII 
cranial nerves132,133. In some MS patients, lesions can alter 
the equilibrium of afferent nerves and chemoreceptors, 
resulting in OSA. Simultaneously, intermittent hypoxia 
could increase oxidative stress and, combined with 
alterations in hypocapnia sensitivity thresholds, may 
worsen neurodegeneration in patients with MS, leading 
to CSA134,135. The main cause lies on alterations in the 
brainstem, which often occur in the late stage of the 
disease123. Braley et al. evaluated apnea-hypopnea and 
central apnea indices in 48 patients with MS compared 
to 48 controls showing significantly worse results among 
MS patients, and suggesting a predisposition for OSA 
and CSA among patients with MS, particularly among 
those with brainstem involvement136.
Diagnosis and assessment of SD can be done using 
polysomnography137. Continuous positive airway 
pressure has been shown to play a significant role in OSA 
and especially-CSA in MS patients138.
CONCLUSION
Otolaryngologic symptoms are common in MS; however, 
they are often overlooked. They can appear either during 
the early stage of the disease, in some cases being the 
presenting symptoms of MS, or at a later stage. Sometimes 
they can even precede the evidence of the lesions at the 
MRI, as reported for sudden SNHL and facial palsy. Many 
of these symptoms significantly affect the quality of life or 
patients and lead to increased morbidity and mortality.
In many cases, otolaryngologic symptoms follow the 
relapsing-remitting phases of the disease, and may 
spontaneously disappear, leading to a delay in MS 
diagnosis when the condition is still undiagnosed. 
Furthermore, the common use of corticosteroids to treat 
these symptoms regardless their origin often results in a 
regression or resolution of the symptom; however, this 
may also delay the diagnosis of MS.
It would be recommended for clinicians involved with the 
diagnosis and therapy of these symptoms to also consider 
MS as a possible cause, especially when associated 
to neurologic symptoms, as they may provide further 
clinical suspect of a central condition. Furthermore, a 
better knowledge of the otolaryngologic symptoms of MS 
is auspicial among otolaryngologists, audiologists and 
phoniatricians as this could help considering MS as an 
etiologic factor in these patients. Last, neurologists should 
consider the role of the otolaryngologist in the clinical 
management of patients with MS to help identifying 
symptoms indicative of disease progression.
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